Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$18.47 -4.0%	$20.72	$18.39 ▼ $30.50	$12.20B	0.98	974,224 shs	951,406 shs
MRNA Moderna	$25.55 -0.7%	$33.88	$23.79 ▼ $170.47	$9.78B	2.23	6.98 million shs	8.67 million shs
TAK Takeda Pharmaceutical	$14.87 -2.1%	$14.32	$12.58 ▼ $15.37	$47.30B	0.39	1.81 million shs	2.06 million shs
TEVA Teva Pharmaceutical Industries	$13.61 -8.4%	$16.67	$12.51 ▼ $22.80	$15.40B	0.82	9.71 million shs	10.02 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	+2.23%	-4.47%	-17.53%	-10.39%	-34.33%
MRNA Moderna	-7.18%	-19.89%	-15.28%	-39.00%	-74.58%
TAK Takeda Pharmaceutical	+1.37%	+0.26%	+2.15%	+14.52%	+12.23%
TEVA Teva Pharmaceutical Industries	-3.04%	-4.37%	-5.01%	-30.11%	+5.06%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	3.879 of 5 stars	4.3	3.0	0.0	0.0	2.6	0.0	3.1
MRNA Moderna	4.2563 of 5 stars	4.0	1.0	0.0	4.6	2.0	2.5	1.3
TAK Takeda Pharmaceutical	2.3685 of 5 stars	0.0	3.0	2.5	0.0	2.6	0.0	2.5
TEVA Teva Pharmaceutical Industries	2.2931 of 5 stars	3.4	3.0	0.8	0.0	2.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.69	Moderate Buy	$41.33	123.82% Upside
MRNA Moderna	2.04	Hold	$59.00	130.91% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
TEVA Teva Pharmaceutical Industries	2.86	Moderate Buy	$23.43	72.21% Upside

Current Analyst Ratings Breakdown

Latest GMAB, TAK, MRNA, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	TAK Takeda Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
4/1/2025	GMAB Genmab A/S	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
3/21/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00
3/13/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
3/11/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00
3/11/2025	GMAB Genmab A/S	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
3/6/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $20.00
2/19/2025	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$96.00 ➝ $78.00
2/18/2025	MRNA Moderna	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$40.00 ➝ $40.00
2/18/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$111.00 ➝ $45.00
2/14/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$45.00

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$21.53B	0.57	$1.25 per share	14.80	$8.04 per share	2.30
MRNA Moderna	$3.20B	3.09	N/A	N/A	$28.33 per share	0.90
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.48 per share	4.27	$15.39 per share	0.97
TEVA Teva Pharmaceutical Industries	$16.54B	0.93	$2.69 per share	5.05	$4.75 per share	2.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.74	10.60	10.37	2.65	36.30%	16.78%	13.79%	5/1/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
TAK Takeda Pharmaceutical	$994.06M	$0.40	37.16	9.01	0.24	4.53%	9.39%	4.53%	5/8/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.45	N/A	5.17	1.44	-9.91%	42.46%	6.65%	5/7/2025 (Estimated)

Latest GMAB, TAK, MRNA, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	GMAB Genmab A/S	$0.26	N/A	N/A	N/A	N/A	N/A
5/1/2025	N/A	MRNA Moderna	-$2.90	N/A	N/A	N/A	$130.35 million	N/A
2/12/2025	Q4 2024	GMAB Genmab A/S	$0.28	$0.57	+$0.29	$0.85	$884.02 million	N/A
1/30/2025	Q3 2025	TAK Takeda Pharmaceutical	$0.34	$0.42	+$0.08	$0.05	N/A	N/A
1/29/2025	Q4 2024	TEVA Teva Pharmaceutical Industries	$0.69	$0.70	+$0.01	-$0.19	$4.10 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.53	3.57%	-8.36%	132.50%	N/A
TEVA Teva Pharmaceutical Industries	$1.01	7.43%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	5.25	5.24
MRNA Moderna	N/A	3.67	3.62
TAK Takeda Pharmaceutical	0.63	1.31	0.72
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
MRNA Moderna	75.33%
TAK Takeda Pharmaceutical	9.17%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
MRNA Moderna	11.00%
TAK Takeda Pharmaceutical	0.04%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	1,660	661.77 million	651.58 million	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

GMAB, TAK, MRNA, and TEVA Headlines

Recent News About These Companies

B. Metzler seel. Sohn & Co. AG Buys 50,995 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 4 at 4:49 AM | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Upgraded by StockNews.com

April 4 at 2:09 AM | americanbankingnews.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Short Interest Up 25.1% in March

April 3 at 6:05 PM | marketbeat.com

Pictet Asset Management Holding SA Buys 52,938 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 3 at 4:18 AM | marketbeat.com

Pharmaceuticals excluded from reciprocal tariffs announced by Trump

April 2 at 7:39 PM | msn.com

Schroder Investment Management Group Increases Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 2 at 4:49 AM | marketbeat.com

DnB Asset Management AS Boosts Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 2 at 4:39 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by UniSuper Management Pty Ltd

April 2 at 4:15 AM | marketbeat.com

Korea Investment CORP Purchases 159,899 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 2 at 4:06 AM | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Shares Up 2.5% - Still a Buy?

April 1 at 3:31 PM | marketbeat.com

Is Teva Pharmaceutical Industries (TEVA) the Most Undervalued Healthcare Stock to Buy According to Analysts?

April 1 at 1:24 PM | msn.com

Latest Teva data in schizophrenia for long-acting injectable of olanzapine

April 1 at 8:22 AM | thepharmaletter.com

Arrowstreet Capital Limited Partnership Has $154.07 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 1 at 5:09 AM | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Buys 70,978 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 1 at 4:05 AM | marketbeat.com

Teva announces presentation of survey study on TEV-‘749

April 1 at 3:22 AM | markets.businessinsider.com

New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

March 31, 2025 | globenewswire.com

Dorsey Wright & Associates Sells 37,975 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 31, 2025 | marketbeat.com

Sei Investments Co. Boosts Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 31, 2025 | marketbeat.com

Okabena Investment Services Inc. Trims Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 30, 2025 | marketbeat.com

Mitsubishi UFJ Trust & Banking Corp Has $12.75 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 30, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Recommendation of "Moderate Buy" by Analysts

March 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Joby Aviation: From Prototype to Profitability
By Jeffrey Neal Johnson | March 11, 2025
View Joby Aviation: From Prototype to Profitability
5 Hot Stock Buys for Investors in April
By Thomas Hughes | April 1, 2025
View 5 Hot Stock Buys for Investors in April
NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?
By Sam Quirke | April 3, 2025
View NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?
Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
By Thomas Hughes | March 18, 2025
View Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Is Intuitive Machines a Buy After Athena's Disappointing Landing?
By Leo Miller | March 18, 2025
View Is Intuitive Machines a Buy After Athena's Disappointing Landing?

GMAB, TAK, MRNA, and TEVA Company Descriptions

Genmab A/S NASDAQ:GMAB

$18.47 -0.77 (-4.02%)

As of 01:39 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Moderna NASDAQ:MRNA

$25.55 -0.18 (-0.70%)

As of 01:39 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Takeda Pharmaceutical NYSE:TAK

$14.86 -0.33 (-2.14%)

As of 01:39 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries NYSE:TEVA

$13.60 -1.25 (-8.38%)

As of 01:39 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time